Pages that link to "Q39020651"

The following pages link to Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden (Q39020651):

Displaying 15 items.

• State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization (Q28079102) (← links)
• Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection (Q36014286) (← links)
• Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. (Q37373261) (← links)
• Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents (Q38637199) (← links)
• Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals (Q38779980) (← links)
• Hepatitis C-A clinical review (Q38812892) (← links)
• Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. (Q38888859) (← links)
• New real-time-PCR method to identify single point mutations in hepatitis C virus. (Q40422658) (← links)
• Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach (Q40696891) (← links)
• Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. (Q52699078) (← links)
• Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank (Q58564271) (← links)
• Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents (Q59125732) (← links)
• Genotypic resistance testing of HCV - is there a clinical need? (Q64986987) (← links)
• Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection (Q90943323) (← links)
• Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance (Q96111290) (← links)